Other News To Note
Tuesday, April 9, 2013
Resverlogix Corp., of Calgary, Alberta, said its board approved a proposal to spin out its subsidiary, RVX Therapeutics Inc., which will focus on drug research and development by leveraging its epigenetics platform.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.